AB239. Icariside II enhances endothelial nitric oxide synthase expression by suppressing miR-155 in diabetic-like human cavernous endothelial cells
Printed Abstracts

AB239. Icariside II enhances endothelial nitric oxide synthase expression by suppressing miR-155 in diabetic-like human cavernous endothelial cells

Ruili Guan, Hongen Lei, Bicheng Yang, Lin Wang, Huixi Li, Zhongcheng Xin

The First Hospital of Peking University, Beijing 100034, China


Background: To investigate the role of Icariside II (ICA II) on endothelial nitric oxide synthase (eNOS) expression regulated by miR-155, the human cavernous endothelial cells (HCECs) were exposed to a diabetic-like environment and treated with ICA II.

Methods: HCECs were treated with 200 µg/mL BSA as the Normal Control group (NC), with 200 µg/mL AGE-BSA plus 250 mg/dL glucose as the diabetes mellitus (DM) group, or with an addition of ICA II in DM group as the treatment group (DM+ICA II). Bioinformatics were first used to predict miRNAs targeting eNOS gene and then potential candidates including miR-155, miR-543, miR-31, miR-429, miR-200b were further verified by real-time PCR in a diabetic-like condition. Expressions levels of miRNAs, eNOS and the receptor for advanced glycation end products (RAGE) were performed by Real-time PCR; Protein expression levels of eNOS and RAGE were analyzed by western blot; nitric oxide (NO) content was detected by DAF-FM DA probe and NaNO2 standard curve methods.

Results: The expression of miR-155 in DM group is significantly higher than that that in the normal control (NC) group, whereas this phenomenon was effectively reversed by ICA II treatment. Furthermore, the miR-155 targeting gene eNOS and its consequent NO product were significantly reduced in DM group, while these changes were also recovered after ICA II treatment.

Conclusions: In this study, we demonstrated that ICA II could promotes eNOS mRNA and protein levels by suppressing miR-155 in HCECs exposed to a diabetic-like environment.

Keywords: Icariside II (ICA II); endothelial nitric oxide synthase (eNOS); diabetes mellitus (DM)


doi: 10.21037/tau.2016.s239


Cite this abstract as: Guan R, Lei H, Yang B, Wang L, Li H, Xin Z. Icariside II enhances endothelial nitric oxide synthase expression by suppressing miR-155 in diabetic-like human cavernous endothelial cells. Transl Androl Urol 2016;5(Suppl 1):AB239. doi: 10.21037/tau.2016.s239

Article Options

Download Citation